Unknown

Dataset Information

0

MiR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models.


ABSTRACT: Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT signaling, could be improved by its combination with a PI3K/AKT/mTOR inhibitor in liver cancer models. The selective pan-AKT inhibitor, MK-2206, or the microRNA-199a-3p were tested in combination with palbociclib in HCC cell lines and in the TG221 HCC transgenic mouse model. The combination palbociclib/MK-2206 was highly effective, but too toxic to be tolerated by mice. Conversely, the combination miR-199a-3p mimics/palbociclib not only induced a complete or partial regression of tumor lesions, but was also well tolerated. After 3 weeks of treatment, the combination produced a significant reduction in number and size of tumor nodules in comparison with palbociclib or miR-199a-3p mimics used as single agents. Moreover, we also reported the efficacy of this combination against sorafenib-resistant cells in vitro and in vivo. At the molecular level, the combination caused the simultaneous decrease of the phosphorylation of both RB1 and of AKT. Our findings provide pre-clinical evidence for the efficacy of the combination miR-199a-3p/palbociclib as anti-HCC treatment or as a new approach to overcome sorafenib resistance.

SUBMITTER: Callegari E 

PROVIDER: S-EPMC9395755 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models.

Callegari Elisa E   Guerriero Paola P   Bassi Cristian C   D'Abundo Lucilla L   Frassoldati Antonio A   Simoni Edi E   Astolfi Laura L   Silini Enrico Maria EM   Sabbioni Silvia S   Negrini Massimo M  

Molecular therapy. Nucleic acids 20220720


Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT signaling, could be improved by its combination with a PI3K/AKT/mTOR inhibitor in liver cancer models. The selective pan-AKT inhibitor, MK-2206, or the microRNA-199a-3p were tested in combination with palbociclib in HCC cell lines and in the TG221  ...[more]

Similar Datasets

| S-EPMC8559701 | biostudies-literature
| S-EPMC4058023 | biostudies-literature
| S-EPMC4484460 | biostudies-literature
| S-EPMC3578415 | biostudies-literature
| S-EPMC8806604 | biostudies-literature
| S-EPMC8571541 | biostudies-literature
| S-EPMC4102790 | biostudies-literature
| S-EPMC7272438 | biostudies-literature
| S-EPMC8735601 | biostudies-literature
| S-EPMC8163806 | biostudies-literature